Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma.
Chief Executive Officer Richard Paulson described Karyopharm as a commercial-stage pharmaceutical company focused on nuclear export inhibition for cancer. He said selinexor is approved in multiple myeloma in the U.S. and in more than 50 countries through partners, and that the company is guiding to approximately $130 million to $150 million in multiple myeloma revenue this year.
